Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JEFFREY S RUMBYRT

Allopathic & Osteopathic Physicians Allergy & Immunology

NPI
1295735694
CMS profile
330548
Location
LAKEWOOD, CO

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$62,198.61

161 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

By paying entity

PY2023 · entire year · sorted by reported total

Page 2 of 4; records 51–100 of 161 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JEFFREY S RUMBYRT

NPI 1295735694 · CMS profile ID 330548

Allopathic & Osteopathic Physicians / Allergy & Immunology

LAKEWOOD, CO

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 4; records 51–100 of 161 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1295735694?year=2023&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JEFFREY S RUMBYRT, NPI 1295735694, CMS profile ID 330548. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 161 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1295735694?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). JEFFREY S RUMBYRT, NPI 1295735694, CMS profile ID 330548. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 161 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1295735694?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
JEFFREY S RUMBYRT, NPI 1295735694, CMS profile ID 330548, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 4; records 51–100 of 161 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1295735694?year=2023&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

161 matching records · $62,198.61 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 161 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 161.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Pharming Healthcare, Inc. $3,500.0008/25/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1029347843 CMS
Pharming Healthcare, Inc. $432.8008/25/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1029347851 CMS
Pharming Healthcare, Inc. $192.6608/25/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1029347857 CMS
BioCryst US Sales Co., LLC $4.3908/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012561547 CMS
CSL Behring $6.6608/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1042915305 CMS
GENZYME CORPORATION $10.9308/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050403391 CMS
Takeda Pharmaceuticals U.S.A., Inc. $9.9708/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055575743 CMS
Takeda Pharmaceuticals U.S.A., Inc. $3,575.0008/11/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055575731 CMS
Takeda Pharmaceuticals U.S.A., Inc. $38.6508/11/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055575737 CMS
Genentech USA, Inc. $13.1508/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040394881 CMS
AstraZeneca Pharmaceuticals LP $42.7508/04/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015391931 CMS
Takeda Pharmaceuticals U.S.A., Inc. $27.8207/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055575725 CMS
GlaxoSmithKline, LLC. $23.8107/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1003264055 CMS
Grifols USA, LLC $9.4907/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011767505 CMS
Takeda Pharmaceuticals U.S.A., Inc. $22.7107/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055575719 CMS
GENZYME CORPORATION $11.2007/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050403377 CMS
AstraZeneca Pharmaceuticals LP $13.2307/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015934459 CMS
BioCryst US Sales Co., LLC $95.9607/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012561465 CMS
BioCryst US Sales Co., LLC $4,140.0007/12/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012561471 CMS
BioCryst US Sales Co., LLC $38.2507/12/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012561475 CMS
AstraZeneca Pharmaceuticals LP $600.0007/11/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011442027 CMS
CSL Behring $7.4607/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1042915287 CMS
BioCryst US Sales Co., LLC $13.4706/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012561519 CMS
Takeda Pharmaceuticals U.S.A., Inc. $109.3506/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055575715 CMS
Genentech USA, Inc. $33.4306/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040394901 CMS
Takeda Pharmaceuticals U.S.A., Inc. $5.5906/22/2023 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055575709 CMS
AstraZeneca Pharmaceuticals LP $14.9406/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015976099 CMS
Pharming Healthcare, Inc. $3,500.0006/21/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1029347813 CMS
Pharming Healthcare, Inc. $116.2406/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1029347819 CMS
Pharming Healthcare, Inc. $9.9606/21/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1029347825 CMS
Pharming Healthcare, Inc. $9.9606/21/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1029347831 CMS
CSL Behring $8.0106/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1042915281 CMS
BioCryst US Sales Co., LLC $39.2306/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012561349 CMS
BioCryst US Sales Co., LLC $366.2606/10/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012561353 CMS
BioCryst US Sales Co., LLC $442.9606/10/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012561357 CMS
BioCryst US Sales Co., LLC $40.0006/10/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012561361 CMS
BioCryst US Sales Co., LLC $76.9706/10/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012561365 CMS
BioCryst US Sales Co., LLC $15.8206/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012561369 CMS
BioCryst US Sales Co., LLC $6,555.0006/10/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012561373 CMS
Takeda Pharmaceuticals U.S.A., Inc. $962.5006/01/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055575703 CMS
GlaxoSmithKline, LLC. $7.3805/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1003262597 CMS
BioCryst US Sales Co., LLC $5.0005/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012561511 CMS
GlaxoSmithKline, LLC. $6.3205/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1003263307 CMS
AstraZeneca Pharmaceuticals LP $13.6105/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016048961 CMS
CSL Behring $2,981.2405/16/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1042915271 CMS
CSL Behring $28.0905/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1042915198 CMS
CSL Behring $46.4005/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1042915221 CMS
CSL Behring $56.5205/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1042915227 CMS
CSL Behring $57.4005/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1042915235 CMS
CSL Behring $13.2205/06/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1042915239 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $31,035.42 62
PY2020 $17,841.20 36
PY2021 $31,695.13 41
PY2022 $61,639.00 112
PY2023 $62,198.61 161
PY2024 $65,729.18 114
PY2025 $77,936.42 166

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $646,245.57 100
PY2024 Principal investigator $420,634.84 37
PY2023 Principal investigator $387,827.62 44
PY2022 Principal investigator $233,553.64 54
PY2021 Principal investigator $185,594.58 68
PY2020 Principal investigator $303,455.02 53
PY2019 Principal investigator $277,681.48 46

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

100 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 SANOFI US SERVICES INC. $669.00 12/22/2025 Non-covered Recipient Entity
Western States Clinical Research In
A Randomized, Double-blind, Placebo-controlled, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab in Participants With Inadequately Controlled Chronic Rhinosinusitis Without Nasal Polyps No dispute reported 06/30/2026 1226108536
Principal investigator 1 SANOFI US SERVICES INC. $1,355.00 12/22/2025 Non-covered Recipient Entity
Western States Clinical Research In
A Randomized, Double-blind, Placebo-controlled, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab in Participants With Inadequately Controlled Chronic Rhinosinusitis Without Nasal Polyps No dispute reported 06/30/2026 1226108544
Principal investigator 1 SANOFI US SERVICES INC. $2,284.00 12/22/2025 Non-covered Recipient Entity
Western States Clinical Research In
A Randomized, Double-blind, Placebo-controlled, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab in Participants With Inadequately Controlled Chronic Rhinosinusitis Without Nasal Polyps No dispute reported 06/30/2026 1226108548
Principal investigator 1 SANOFI US SERVICES INC. $33,980.00 12/22/2025 Non-covered Recipient Entity
Western States Clinical Research In
A Randomized, Double-blind, Placebo-controlled, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab in Participants With Inadequately Controlled Chronic Rhinosinusitis Without Nasal Polyps No dispute reported 06/30/2026 1226108555
Principal investigator 1 ABBVIE INC. $2,618.20 12/18/2025 Non-covered Recipient Entity
WESTERN STATES CLINICAL
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202531374
Principal investigator 1 ABBVIE INC. $213.49 12/09/2025 Non-covered Recipient Entity
WESTERN STATES CLINICAL
A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202529766
Principal investigator 1 SANOFI US SERVICES INC. $250.00 12/08/2025 Non-covered Recipient Entity
Western States Clinical Research In
An Open Label Extension Study to Evaluate the Long-term Safety and Efficacy of Subcutaneous Lunsekimig in Adult Participants With Moderatetosevere Asthma Who Participated in Study DRI16762 No dispute reported 06/30/2026 1226108527
Principal investigator 1 ABBVIE INC. $6,298.00 12/04/2025 Non-covered Recipient Entity
WESTERN STATES CLINICAL
A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202528860
Principal investigator 1 GlaxoSmithKline, LLC. $1,698.00 11/25/2025 Non-covered Recipient Entity
WESTERN STATES CLINICAL RESEARCH INC
A PROSPECTIVE COHORT STUDY OF PATIENTS WITH REFRACTORY OR UNEXPLAINED No dispute reported 06/30/2026 1192189252
Principal investigator 1 GlaxoSmithKline, LLC. $6,500.00 11/25/2025 Non-covered Recipient Entity
WESTERN STATES CLINICAL RESEARCH INC
A PROSPECTIVE COHORT STUDY OF PATIENTS WITH REFRACTORY OR UNEXPLAINED No dispute reported 06/30/2026 1192189257
Principal investigator 1 SANOFI US SERVICES INC. $8,400.00 11/24/2025 Non-covered Recipient Entity
Western States Clinical Research In
An Open Label Extension Study to Evaluate the Long-term Safety and Efficacy of Subcutaneous Lunsekimig in Adult Participants With Moderatetosevere Asthma Who Participated in Study DRI16762 No dispute reported 06/30/2026 1226108532
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $85,114.20 11/21/2025 Non-covered Recipient Entity
Western States Clinical Research, Inc
A Phase 3, Multi-Center, Multi-National, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of CC-93538 in Adult and Adolescent Subjects with Active Eosinophilic Esophagitis. No dispute reported 06/30/2026 1235991664
Principal investigator 1 GlaxoSmithKline, LLC. $44,523.27 11/21/2025 Non-covered Recipient Entity
WESTERN STATES CLINICAL RESEARCH INC
A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192187967
Principal investigator 1 Phathom Pharmaceuticals, Inc. $5,906.25 11/19/2025 Non-covered Recipient Entity
WESTERN STATES CLINICAL RESEAR
EoE-201 No dispute reported 06/30/2026 1224869002
Principal investigator 1 Phathom Pharmaceuticals, Inc. $337.50 11/19/2025 Non-covered Recipient Entity
WESTERN STATES CLINICAL RESEAR
EoE-201 No dispute reported 06/30/2026 1224869006
Principal investigator 1 SANOFI US SERVICES INC. $3,978.00 11/17/2025 Non-covered Recipient Entity
Western States Clinical Research In
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma No dispute reported 06/30/2026 1226108522
Principal investigator 1 GlaxoSmithKline, LLC. $1,307.00 11/14/2025 Non-covered Recipient Entity
WESTERN STATES CLINICAL RESEARCH INC
A PROSPECTIVE COHORT STUDY OF PATIENTS WITH REFRACTORY OR UNEXPLAINED No dispute reported 06/30/2026 1192187962
Principal investigator 1 GlaxoSmithKline, LLC. $3,921.00 11/07/2025 Non-covered Recipient Entity
WESTERN STATES CLINICAL RESEARCH INC
A PROSPECTIVE COHORT STUDY OF PATIENTS WITH REFRACTORY OR UNEXPLAINED No dispute reported 06/30/2026 1192187958
Principal investigator 1 ABBVIE INC. $4,594.35 11/05/2025 Non-covered Recipient Entity
WESTERN STATES CLINICAL
A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202522205
Principal investigator 1 SANOFI US SERVICES INC. $66.00 11/04/2025 Non-covered Recipient Entity
Western States Clinical Research In
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma No dispute reported 06/30/2026 1226108496
Principal investigator 1 SANOFI US SERVICES INC. $481.00 11/04/2025 Non-covered Recipient Entity
Western States Clinical Research In
An Open Label Extension Study to Evaluate the Long-term Safety and Efficacy of Subcutaneous Lunsekimig in Adult Participants With Moderatetosevere Asthma Who Participated in Study DRI16762 No dispute reported 06/30/2026 1226108506
Principal investigator 1 SANOFI US SERVICES INC. $4,393.00 11/04/2025 Non-covered Recipient Entity
Western States Clinical Research In
An Open Label Extension Study to Evaluate the Long-term Safety and Efficacy of Subcutaneous Lunsekimig in Adult Participants With Moderatetosevere Asthma Who Participated in Study DRI16762 No dispute reported 06/30/2026 1226108511
Principal investigator 1 SANOFI US SERVICES INC. $5,958.00 11/04/2025 Non-covered Recipient Entity
Western States Clinical Research In
An Open Label Extension Study to Evaluate the Long-term Safety and Efficacy of Subcutaneous Lunsekimig in Adult Participants With Moderatetosevere Asthma Who Participated in Study DRI16762 No dispute reported 06/30/2026 1226108516
Principal investigator 1 GlaxoSmithKline, LLC. $2,150.00 11/03/2025 Non-covered Recipient Entity
WESTERN STATES CLINICAL RESEARCH INC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192187975
Principal investigator 1 GlaxoSmithKline, LLC. $1,350.00 11/03/2025 Non-covered Recipient Entity
WESTERN STATES CLINICAL RESEARCH INC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192189264
Principal investigator 1 ABBVIE INC. $1,500.00 10/28/2025 Non-covered Recipient Entity
WESTERN STATES CLINICAL
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202518783
Principal investigator 1 SANOFI US SERVICES INC. $125.00 10/27/2025 Non-covered Recipient Entity
Western States Clinical Research In
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma No dispute reported 06/30/2026 1226108481
Principal investigator 1 SANOFI US SERVICES INC. $5,909.00 10/27/2025 Non-covered Recipient Entity
Western States Clinical Research In
A Randomized, Double-blind, Placebo-controlled, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab in Participants With Inadequately Controlled Chronic Rhinosinusitis Without Nasal Polyps No dispute reported 06/30/2026 1226108487
Principal investigator 1 SANOFI US SERVICES INC. $657.99 10/27/2025 Non-covered Recipient Entity
Western States Clinical Research In
A Randomized, Double-blind, Placebo-controlled, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab in Participants With Inadequately Controlled Chronic Rhinosinusitis Without Nasal Polyps No dispute reported 06/30/2026 1226108491
Principal investigator 1 GlaxoSmithKline, LLC. $477.00 10/22/2025 Non-covered Recipient Entity
WESTERN STATES CLINICAL RESEARCH INC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192187980
Principal investigator 1 SANOFI US SERVICES INC. $111.96 10/20/2025 Non-covered Recipient Entity
Western States Clinical Research In
A Randomized, Double-blind, Placebo-controlled, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab in Participants With Inadequately Controlled Chronic Rhinosinusitis Without Nasal Polyps No dispute reported 06/30/2026 1226108476
Principal investigator 1 ABBVIE INC. $55.33 10/16/2025 Non-covered Recipient Entity
WESTERN STATES CLINICAL
A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202517261
Principal investigator 1 SANOFI US SERVICES INC. $300.00 10/14/2025 Non-covered Recipient Entity
Western States Clinical Research In
An Open Label Extension Study to Evaluate the Long-term Safety and Efficacy of Subcutaneous Lunsekimig in Adult Participants With Moderatetosevere Asthma Who Participated in Study DRI16762 No dispute reported 06/30/2026 1226108470
Principal investigator 1 ABBVIE INC. $1,973.60 10/09/2025 Non-covered Recipient Entity
WESTERN STATES CLINICAL
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202515169
Principal investigator 1 ABBVIE INC. $7,181.05 10/09/2025 Non-covered Recipient Entity
WESTERN STATES CLINICAL
A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202515171
Principal investigator 1 SANOFI US SERVICES INC. $4,083.00 10/06/2025 Non-covered Recipient Entity
Western States Clinical Research In
A Randomized, Double-blind, Placebo-controlled, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab in Participants With Inadequately Controlled Chronic Rhinosinusitis Without Nasal Polyps No dispute reported 06/30/2026 1226108458
Principal investigator 1 SANOFI US SERVICES INC. $2,250.00 10/06/2025 Non-covered Recipient Entity
Western States Clinical Research In
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma No dispute reported 06/30/2026 1226108465
Principal investigator 1 GlaxoSmithKline, LLC. $250.00 09/25/2025 Non-covered Recipient Entity
WESTERN STATES CLINICAL RESEARCH INC
A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192187970
Principal investigator 1 Phathom Pharmaceuticals, Inc. $1,066.50 09/24/2025 Non-covered Recipient Entity
WESTERN STATES CLINICAL RESEARCH
EoE-201 No dispute reported 06/30/2026 1224868845
Principal investigator 1 SANOFI US SERVICES INC. $24,900.00 09/22/2025 Non-covered Recipient Entity
Western States Clinical Research In
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment No dispute reported 06/30/2026 1226108442
Principal investigator 1 SANOFI US SERVICES INC. $1,000.00 09/22/2025 Non-covered Recipient Entity
Western States Clinical Research In
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma No dispute reported 06/30/2026 1226108446
Principal investigator 1 SANOFI US SERVICES INC. $375.00 09/22/2025 Non-covered Recipient Entity
Western States Clinical Research In
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma No dispute reported 06/30/2026 1226108453
Principal investigator 1 GlaxoSmithKline, LLC. $110.00 09/12/2025 Non-covered Recipient Entity
WESTERN STATES CLINICAL RESEARCH INC
A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192189244
Principal investigator 1 GlaxoSmithKline, LLC. $2,420.00 09/12/2025 Non-covered Recipient Entity
WESTERN STATES CLINICAL RESEARCH INC
A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192189272
Principal investigator 1 SANOFI US SERVICES INC. $3,140.10 09/08/2025 Non-covered Recipient Entity
Western States Clinical Research In
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma No dispute reported 06/30/2026 1226108424
Principal investigator 1 SANOFI US SERVICES INC. $250.00 09/08/2025 Non-covered Recipient Entity
Western States Clinical Research In
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma No dispute reported 06/30/2026 1226108431
Principal investigator 1 ABBVIE INC. $14,058.25 09/04/2025 Non-covered Recipient Entity
WESTERN STATES CLINICAL
A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202509140
Principal investigator 1 ABBVIE INC. $2,160.90 09/03/2025 Non-covered Recipient Entity
WESTERN STATES CLINICAL
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202507631
Principal investigator 1 SANOFI US SERVICES INC. $12,154.00 08/25/2025 Non-covered Recipient Entity
Western States Clinical Research In
A Randomized, Double-blind, Placebo-controlled, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab in Participants With Inadequately Controlled Chronic Rhinosinusitis Without Nasal Polyps No dispute reported 06/30/2026 1226108418
Principal investigator 1 SANOFI US SERVICES INC. $1,919.91 08/25/2025 Non-covered Recipient Entity
Western States Clinical Research In
A Randomized, Double-blind, Placebo-controlled, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab in Participants With Inadequately Controlled Chronic Rhinosinusitis Without Nasal Polyps No dispute reported 06/30/2026 1226108437
Principal investigator 1 ABBVIE INC. $114.72 08/21/2025 Non-covered Recipient Entity
WESTERN STATES CLINICAL
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202505425
Principal investigator 1 ABBVIE INC. $50.74 08/21/2025 Non-covered Recipient Entity
WESTERN STATES CLINICAL
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202505437
Principal investigator 1 ABBVIE INC. $159.70 08/21/2025 Non-covered Recipient Entity
WESTERN STATES CLINICAL
A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202505439
Principal investigator 1 ABBVIE INC. $102.91 08/21/2025 Non-covered Recipient Entity
WESTERN STATES CLINICAL
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202505441
Principal investigator 1 ABBVIE INC. $43.57 08/21/2025 Non-covered Recipient Entity
WESTERN STATES CLINICAL
A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202505443
Principal investigator 1 ABBVIE INC. $165.15 08/21/2025 Non-covered Recipient Entity
WESTERN STATES CLINICAL
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202505461
Principal investigator 1 SANOFI US SERVICES INC. $6,732.00 08/11/2025 Non-covered Recipient Entity
Western States Clinical Research In
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma No dispute reported 06/30/2026 1226108410
Principal investigator 1 ABBVIE INC. $842.00 08/07/2025 Non-covered Recipient Entity
WESTERN STATES CLINICAL
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202503845
Principal investigator 1 ABBVIE INC. $1,961.70 08/06/2025 Non-covered Recipient Entity
WESTERN STATES CLINICAL
A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202502891
Principal investigator 1 ABBVIE INC. $1,742.70 08/05/2025 Non-covered Recipient Entity
WESTERN STATES CLINICAL
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202501602
Principal investigator 1 SANOFI US SERVICES INC. $1,750.00 07/28/2025 Non-covered Recipient Entity
Western States Clinical Research In
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma No dispute reported 06/30/2026 1226108405
Principal investigator 1 SANOFI US SERVICES INC. $4,584.00 07/21/2025 Non-covered Recipient Entity
Western States Clinical Research In
An Open Label Extension Study to Evaluate the Long-term Safety and Efficacy of Subcutaneous Lunsekimig in Adult Participants With Moderatetosevere Asthma Who Participated in Study DRI16762 No dispute reported 06/30/2026 1226108398
Principal investigator 1 SANOFI US SERVICES INC. $9,368.10 07/14/2025 Non-covered Recipient Entity
Western States Clinical Research In
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma No dispute reported 06/30/2026 1226108387
Principal investigator 1 ABBVIE INC. $9,920.10 07/08/2025 Non-covered Recipient Entity
WESTERN STATES CLINICAL
A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202497142
Principal investigator 1 GlaxoSmithKline, LLC. $1,432.00 07/07/2025 Non-covered Recipient Entity
WESTERN STATES CLINICAL RESEARCH INC
A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192187985
Principal investigator 1 ABBVIE INC. $5,530.20 07/02/2025 Non-covered Recipient Entity
WESTERN STATES CLINICAL
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202494031
Principal investigator 1 SANOFI US SERVICES INC. $875.00 07/02/2025 Non-covered Recipient Entity
Western States Clinical Research In
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma No dispute reported 06/30/2026 1226108379
Principal investigator 1 SANOFI US SERVICES INC. $250.00 07/02/2025 Non-covered Recipient Entity
Western States Clinical Research In
An Open Label Extension Study to Evaluate the Long-term Safety and Efficacy of Subcutaneous Lunsekimig in Adult Participants With Moderatetosevere Asthma Who Participated in Study DRI16762 No dispute reported 06/30/2026 1226108394
Principal investigator 1 AstraZeneca Pharmaceuticals LP $98.56 06/23/2025 Non-covered Recipient Entity
WESTERN STATES CLINICAL RESEARCH INC
A 24-Week Efficacy and Safety Study to Assess Budesonide and Formoterol Fumarate Metered Dose Inhaler in Adult and Adolescent Participants With Inadequately Controlled Asthma No dispute reported 06/30/2026 1185547761
Principal investigator 1 SANOFI US SERVICES INC. $11,618.10 06/16/2025 Non-covered Recipient Entity
Western States Clinical Research In
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma No dispute reported 06/30/2026 1226108375
Principal investigator 1 GlaxoSmithKline, LLC. $1,580.00 06/06/2025 Non-covered Recipient Entity
WESTERN STATES CLINICAL RESEARCH INC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192187367
Principal investigator 1 ABBVIE INC. $1,665.60 06/03/2025 Non-covered Recipient Entity
WESTERN STATES CLINICAL
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202488739
Principal investigator 1 ABBVIE INC. $818.00 05/13/2025 Non-covered Recipient Entity
WESTERN STATES CLINICAL
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202484759
Principal investigator 1 SANOFI US SERVICES INC. $11,650.50 05/12/2025 Non-covered Recipient Entity
Western States Clinical Research In
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma No dispute reported 06/30/2026 1226108361
Principal investigator 1 ABBVIE INC. $331.90 05/06/2025 Non-covered Recipient Entity
WESTERN STATES CLINICAL
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202482207
Principal investigator 1 Phathom Pharmaceuticals, Inc. $11,450.00 04/18/2025 Non-covered Recipient Entity
WESTERN STATES CLINICAL RESEARCH
EoE-201 No dispute reported 06/30/2026 1224868923
Principal investigator 1 SANOFI US SERVICES INC. $14,241.60 04/14/2025 Non-covered Recipient Entity
Western States Clinical Research In
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma No dispute reported 06/30/2026 1226108349
Principal investigator 1 GlaxoSmithKline, LLC. $662.15 04/04/2025 Non-covered Recipient Entity
WESTERN STATES CLINICAL RESEARCH INC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192189261
Principal investigator 1 ABBVIE INC. $13,648.50 04/03/2025 Non-covered Recipient Entity
WESTERN STATES CLINICAL
A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202470070
Principal investigator 1 ABBVIE INC. $995.70 04/03/2025 Non-covered Recipient Entity
WESTERN STATES CLINICAL
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202470106
Principal investigator 1 SANOFI US SERVICES INC. $260.00 04/02/2025 Non-covered Recipient Entity
Western States Clinical Research In
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma No dispute reported 06/30/2026 1226108343
Principal investigator 1 SANOFI US SERVICES INC. $9,058.50 03/17/2025 Non-covered Recipient Entity
Western States Clinical Research In
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma No dispute reported 06/30/2026 1226108326
Principal investigator 1 GlaxoSmithKline, LLC. $10,073.00 03/14/2025 Non-covered Recipient Entity
WESTERN STATES CLINICAL RESEARCH INC
A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192189248
Principal investigator 1 GlaxoSmithKline, LLC. $1,894.00 03/07/2025 Non-covered Recipient Entity
WESTERN STATES CLINICAL RESEARCH INC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192187988
Principal investigator 1 ABBVIE INC. $663.80 03/06/2025 Non-covered Recipient Entity
WESTERN STATES CLINICAL
M16-047 - A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202458813
Principal investigator 1 SANOFI US SERVICES INC. $13,402.00 03/04/2025 Non-covered Recipient Entity
Western States Clinical Research In
An Open Label Extension Study to Evaluate the Long-term Safety and Efficacy of Subcutaneous Lunsekimig in Adult Participants With Moderatetosevere Asthma Who Participated in Study DRI16762 No dispute reported 06/30/2026 1226108286
Principal investigator 1 SANOFI US SERVICES INC. $13,760.00 03/04/2025 Non-covered Recipient Entity
Western States Clinical Research In
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma No dispute reported 06/30/2026 1226108335
Principal investigator 1 SANOFI US SERVICES INC. $10,430.00 02/24/2025 Non-covered Recipient Entity
Western States Clinical Research In
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma No dispute reported 06/30/2026 1226108293
Principal investigator 1 SANOFI US SERVICES INC. $390.60 02/24/2025 Non-covered Recipient Entity
Western States Clinical Research In
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma No dispute reported 06/30/2026 1226108312
Principal investigator 1 AstraZeneca Pharmaceuticals LP $44,333.13 02/21/2025 Non-covered Recipient Entity
WESTERN STATES CLINICAL RESEARCH INC
A Randomized, Placebo-controlled, Double-blind, Multicenter, 12 Week, 3-Way, Partial-replicate Crossover Pharmacodynamic Study to Assess the Equivalence of Budesonide and Albuterol (BDA) Delivered by MDI HFO Compared with BDA Delivered by MDI HFA in Participants with Asthma No dispute reported 06/30/2026 1185547765
Principal investigator 1 SANOFI US SERVICES INC. $25,608.60 02/18/2025 Non-covered Recipient Entity
Western States Clinical Research In
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma No dispute reported 06/30/2026 1226108320
Principal investigator 1 SANOFI US SERVICES INC. $12,800.00 02/18/2025 Non-covered Recipient Entity
Western States Clinical Research In
A Randomized, Double-blind, Placebo-controlled, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab in Participants With Inadequately Controlled Chronic Rhinosinusitis Without Nasal Polyps No dispute reported 06/30/2026 1226108330
Principal investigator 1 GlaxoSmithKline, LLC. $1,039.00 02/07/2025 Non-covered Recipient Entity
WESTERN STATES CLINICAL RESEARCH INC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192098134
Principal investigator 1 ABBVIE INC. $1,357.60 02/05/2025 Non-covered Recipient Entity
WESTERN STATES CLINICAL
M16-047 - A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202445192
Principal investigator 1 SANOFI US SERVICES INC. $9,375.00 02/04/2025 Non-covered Recipient Entity
Western States Clinical Research In
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma No dispute reported 06/30/2026 1226108299
Principal investigator 1 SANOFI US SERVICES INC. $6,125.00 01/21/2025 Non-covered Recipient Entity
Western States Clinical Research In
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma No dispute reported 06/30/2026 1226108305
Principal investigator 1 Celgene Corporation $3,250.00 01/17/2025 Non-covered Recipient Entity
Western States Clinical Research, Inc
A Multi-Center, Multi-National, Randomized, Double-Blind, Placebo-Controlled Induction and Long-term Controlled Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Subjects with Active Eosinophilic Esophagitis. No dispute reported 06/30/2026 1222305362
Principal investigator 1 Celgene Corporation $30,160.95 01/13/2025 Non-covered Recipient Entity
Western States Clinical Research, Inc
A Phase 3, Multi-Center, Multi-National, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of CC-93538 in Adult and Adolescent Subjects with Active Eosinophilic Esophagitis. No dispute reported 06/30/2026 1222305340
Principal investigator 1 GlaxoSmithKline, LLC. $766.65 01/13/2025 Non-covered Recipient Entity
WESTERN STATES CLINICAL RESEARCH INC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192189267
Principal investigator 1 AstraZeneca Pharmaceuticals LP $20,338.69 01/08/2025 Non-covered Recipient Entity
WESTERN STATES CLINICAL RESEARCH INC
A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler MDI Relative to Budesonide and Formoterol Fumarate MDI and Symbicort pMDI in Adult and Adolescent Participants with Inadequately Controlled Asthma No dispute reported 06/30/2026 1185547763